Unlock instant, AI-driven research and patent intelligence for your innovation.

Function and application of SIKB kinase omega-inhibitor in treating fatty liver and type II diabetes

A technology for diabetes and fatty liver, applied in gene therapy, metabolic diseases, preparations for in vivo experiments, etc., can solve problems such as unclear effects

Inactive Publication Date: 2017-02-22
WUHAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its role in fatty liver and type 2 diabetes is still unclear and needs further research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Function and application of SIKB kinase omega-inhibitor in treating fatty liver and type II diabetes
  • Function and application of SIKB kinase omega-inhibitor in treating fatty liver and type II diabetes
  • Function and application of SIKB kinase omega-inhibitor in treating fatty liver and type II diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] [Example 1] Obtaining mouse fatty liver and type II diabetes model (diet induced obesity, DIO)

[0033] (1) Grouping of experimental animals: 8-week-old, male, WT mice and SIKE-KO mice were selected and given two special diets, D12942 high-fat diet (High fat diet, HFD) and D12450B low-fat diet (Normal chow , NC) feeding, that is WTNC group, KO NC group, WT HFD group, KO HFD group a total of 4 groups.

[0034] (2) The model induces the operation process through high-fat feed:

[0035] Using WT and KO mice, the DIO model was established, and the phenotype correlation analysis was carried out to clarify the role of the SIKE gene on fatty liver and type II diabetes. 8-week-old, male, WT mice and SIKE-KO (TG) mice were selected and fed with two special diets, D12942 high-fat diet (Highfat diet, HFD) and D12450B low-fat diet (Normal chow, NC), respectively. That is WT NC group, KO NC group, WTHFD group, KO HFD group, a total of 4 groups. The food intake of the mice was rec...

Embodiment 2

[0036] [Example 2] Determination of mouse body weight and blood sugar level

[0037] (1) Detection of fasting body weight of mice

[0038] 1) Weight detection.

[0039] ①Fasting: fast the mice to be tested at 8:00 am (without water), and start the experimental operation at 2:00 pm.

[0040] ② Weighing: Weigh at 0 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks respectively. In a small bucket, measure the weight and record the data. Feed amount detection: After the weighing operation is completed, add feed to the mice, and record the amount of feed for the mice on the dynamic electronic balance.

[0041] (2) Fasting blood glucose level detection experiment

[0042] All the mice to be tested were fasted from 8:00 am to 2:00 pm (without water), that is, the experimental operation was started after 6 hours of fasting.

[0043] ① Blood glucose meter preparation: Check the battery of the blood glucose meter (Johnson & Johnson, ONETOUCH, USA), press the switch o...

Embodiment 3

[0048] [Example 3] Glucose tolerance test (intraperitoneal glucose tolerance test, IPGTT)

[0049] In the 11th week of the experiment, the intraperitoneal injection of glucose test (IPGTT) was performed to evaluate the glucose tolerance of the mice.

[0050] (1) Before measuring blood glucose, measure the fasting body weight of the mice, and calculate the injection volume of glucose based on 10 μL / g.

[0051] (2) First detect the fasting blood glucose at 0 minutes before the glucose injection, and inject the glucose solution intraperitoneally quickly after the detection is completed.

[0052] (3) Operation method of intraperitoneal injection: ①Fix the mouse; grab the mouse, grab the tail of the mouse with the little finger and ring finger of the left hand, and grab the neck of the mouse with the other three fingers, so that the head of the mouse is downward, and the The abdomen of the mouse is fully exposed. ②Needle positioning and injection: insert the needle from the side ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses function and application of SIKE gene in treating fatty liver and type II diabetes. SIKE gene knockout mouse and wild C57 mouse as the experiment object are used as experiemental objects; through fatty mouse model inducted by high fat diet, the result shows that the SIKE-KO mouse is fat by comparing with wild C57 mouse, the fasting blood-glucose level is higher than the WT mouse in reference group, and liver function is obviously worse than WT mouse. The experiment of intraperitoneal injection glucose tolerance finds that the glucose tolerance ability SIKE-KO mouse is obviously weakened. The liver weight and liver weight ratio, lipid component, glycogen content pathological staining result and others indicate that the fatty liver disease of the SIKE-KO mouse with high fatty diet is obviously serious, and the lipid accumulation is significantly increased. Therefore, the SIKE can be used as the drug target for screening and treating fatty liver and type II diabetes; the accelerant can be used for preparing drugs for treating fatty liver and type II diabetes.

Description

technical field [0001] The invention belongs to the field of gene function and application, and particularly relates to the application of an IκB kinase ε inhibitor (suppressor of IKKε, SIKE) as a target gene in the preparation of drugs for preventing, alleviating and / or treating fatty liver and / or type II diabetes. Background technique [0002] In recent years, with the gradual aging of the population and changes in lifestyles, the number of people with metabolic abnormalities such as obesity, diabetes, non-alcoholic fatty liver disease, and metabolic syndrome has risen sharply, becoming a serious public health problem and bringing a heavy economic burden to our country. and social burden. At present, although there are many kinds of hypoglycemic drugs on the market, the current situation of diabetes treatment is still not optimistic. According to statistics, there were 285 million diabetics in the world in 2010, and this figure will increase to 439 million by 2030, which ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K49/00A61K45/00A61P1/16A61P3/10
CPCA61K48/005A61K45/00A61K49/0008
Inventor 李红良张晓晶王丕晓
Owner WUHAN UNIV